Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC70 Torin2
1.0
mTOR/ATM/ATR
PI3K/mTOR
 -0.5550 0.52095
PDX1328 Volasertib
0.031623
PLK
Cell cycle
 -0.5546 0.38151
PDX1328 Volasertib
1.0
PLK
Cell cycle
 -0.5543 0.30299
HCC70 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 -0.5531 0.18001
BT-20 Taxol
0.31623
Chemo
Chemotherapy
 -0.5527 0.73180
BT-20 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.5514 0.71187
PDXHCI002 Vorinostat
3.1623
HDAC
Misc
 -0.5508 0.74305
HCC70 Luminespib
0.31623
HSP90
Misc
 -0.5505 0.47778
HCC1428 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.5503 0.56120
HCC1428 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.5502 0.53304
PDX1328 Tivantinib
10.0
MET
RTK
 -0.5501 0.33061
MDA-MB-361 Taxol
0.031623
Chemo
Chemotherapy
 -0.5498 0.38317
MDA-MB-468 Taxol
0.1
Chemo
Chemotherapy
 -0.5472 0.80695
HCC1500 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.5459 0.41413
HCC1806 Topotecan
10.0
Topo I
Chemotherapy
 -0.5458 0.55016
MDA-MB-453 Luminespib
0.031623
HSP90
Misc
 -0.5454 0.50222
HCC70 Luminespib
0.031623
HSP90
Misc
 -0.5427 0.46096
HCC70 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.5399 0.20623
SK-BR-3 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.5397 0.49493
MDA-MB-453 Luminespib
0.1
HSP90
Misc
 -0.5361 0.49872
BT-20 Volasertib
0.31623
PLK
Cell cycle
 -0.5339 0.71936
MDA-MB-134-VI AZD7762
3.1623
CHK1/2
Cell cycle
 -0.5337 0.29934
PDX1328 Taxol
0.31623
Chemo
Chemotherapy
 -0.5332 0.30897
MDA-MB-361 Tivantinib
3.1623
MET
RTK
 -0.5326 0.43436
HCC70 Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 -0.5323 0.53772